To our knowledge, there are no FDA-approved drugs that are added routinely into clinical trials that target the Wnt pathway [24], nor are there any RSPO2 inhibitors that have been granted FDA approval for cancer treatments. The gene discussed is RSPO2; the disease is cancer.